Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.66 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HMOX1 | P09601 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409741 | 0.86 | HMOX1 (0.72) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| Bromide SCHEMBL29223796 | 0.85 | HMOX1 (0.70) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| Hydrochloric Acid SCHEMBL7527357 | 0.85 | HMOX1 (0.70) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| SCHEMBL10496235 | 0.83 | TBXAS1 (0.56) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| SCHEMBL27460992 | 0.83 | TBXAS1 (0.60) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| SCHEMBL6987156 | 0.83 | CYP19A1 (0.69) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| SCHEMBL6986190 | 0.83 | HMOX1 (0.79) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| SCHEMBL16719036 | 0.83 | CYP19A1 (0.81) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 | |
| SCHEMBL10788342 | 0.83 | TBXAS1 (0.65) | TBXAS1CYP19A1KMT2AHMOX1 | |
| SCHEMBL4316370 | 0.83 | CYP11B1 (0.69) | CYP11B1TBXAS1CYP19A1KMT2AHMOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-08-02 | — | — | US | claimed |
| WO-2012019093-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-09 | — | — | WO | claimed |
| US-8906943-B2 | Synthetic compounds and methods to decrease nicotine self-administration | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-12-09 | — | — | US | disclosed |
| US-8906943-B2 | Synthetic compounds and methods to decrease nicotine self-administration | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-12-09 | — | — | US | disclosed |
| US-8906943-B2 | Synthetic compounds and methods to decrease nicotine self-administration | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-12-09 | — | — | US | disclosed |
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2012019093-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012019093-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-09 | — | — | WO | disclosed |
| US-4925851-A | ANTITUMOR AGENTS; LEUKEMIA | SANDOZ PHARMACEUTICALS CORP. (US) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | SLC6A3, NNT, SLC6A2 | CYP11B1 1125/4885TBXAS1 3095/4885CYP19A1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.